{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:07:29Z","timestamp":1777334849298,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,10,17]],"date-time":"2014-10-17T00:00:00Z","timestamp":1413504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"},{"start":{"date-parts":[[2014,10,17]],"date-time":"2014-10-17T00:00:00Z","timestamp":1413504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2014.71","type":"journal-article","created":{"date-parts":[[2014,10,17]],"date-time":"2014-10-17T13:16:12Z","timestamp":1413551772000},"page":"e251-e251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed\/refractory lymphoma"],"prefix":"10.1038","volume":"4","author":[{"given":"S E","family":"Assouline","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B D","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Rifkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Hamburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A-M","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Di Bacco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Shou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,17]]},"reference":[{"key":"BFbcj201471_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9\u201329.","journal-title":"CA Cancer J Clin"},{"key":"BFbcj201471_CR2","unstructured":"National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphoma. V.4. 2014. https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL=http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf."},{"key":"BFbcj201471_CR3","unstructured":"National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma. V.2. 2014. https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL=http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf."},{"key":"BFbcj201471_CR4","unstructured":"Millennium Pharmaceuticals Inc VELCADE\u00ae (bortezomib) for Injection\u2014Full Prescribing information, version 16. 2014. www.velcade.com\/files\/pdfs\/velcade_prescribing_information.pdf."},{"key":"BFbcj201471_CR5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1158\/1078-0432.CCR-08-2647","volume":"16","author":"OA O'Connor","year":"2010","unstructured":"O'Connor OA, Portlock C, Moskowitz C, Hamlin P, Straus D, Gerecitano J et al. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res 2010; 16: 719\u2013726.","journal-title":"Clin Cancer Res"},{"key":"BFbcj201471_CR6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S1470-2045(11)70150-4","volume":"12","author":"B Coiffier","year":"2011","unstructured":"Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol 2011; 12: 773\u2013784.","journal-title":"Lancet Oncol"},{"key":"BFbcj201471_CR7","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","volume":"117","author":"FM Foss","year":"2011","unstructured":"Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K . Peripheral T-cell lymphoma. Blood 2011; 117: 6756\u20136767.","journal-title":"Blood"},{"key":"BFbcj201471_CR8","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","volume":"25","author":"PL Zinzani","year":"2007","unstructured":"Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 4293\u20134297.","journal-title":"J Clin Oncol"},{"key":"BFbcj201471_CR9","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","volume":"29","author":"J Ruan","year":"2011","unstructured":"Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29: 690\u2013697.","journal-title":"J Clin Oncol"},{"key":"BFbcj201471_CR10","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","volume":"113","author":"K Dunleavy","year":"2009","unstructured":"Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009; 113: 6069\u20136076.","journal-title":"Blood"},{"key":"BFbcj201471_CR11","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","volume":"70","author":"E Kupperman","year":"2010","unstructured":"Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010; 70: 1970\u20131980.","journal-title":"Cancer Res"},{"key":"BFbcj201471_CR12","doi-asserted-by":"publisher","first-page":"7313","DOI":"10.1158\/1078-0432.CCR-11-0636","volume":"17","author":"EC Lee","year":"2011","unstructured":"Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J et al. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res 2011; 17: 7313\u20137323.","journal-title":"Clin Cancer Res"},{"key":"BFbcj201471_CR13","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","volume":"124","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D et al. Weekly dosing of the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma: results from a phase 1 study. Blood 2014; 124: 1047\u20131055.","journal-title":"Blood"},{"key":"BFbcj201471_CR14","first-page":"332","volume":"120","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Hamadani M, Stewart AK et al. A phase 1\/2 study of weekly mln9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM). ASH Annual Meeting Abstracts 2012; 120: 332.","journal-title":"ASH Annual Meeting Abstracts"},{"key":"BFbcj201471_CR15","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1182\/blood-2014-01-548826","volume":"124","author":"PG Richardson","year":"2014","unstructured":"Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD et al. Phase 1 study of twice-weekly dosing of investigational oral proteasome inhibitor ixazomib in patients with relapsed and\/or refractory multiple myeloma. Blood 2014; 124: 1038\u20131046.","journal-title":"Blood"},{"key":"BFbcj201471_CR16","first-page":"731","volume":"120","author":"G Merlini","year":"2012","unstructured":"Merlini G, Sanchorawala V, Zonder JA, Kukreti V, Schonland SO, Jaccard A et al. MLN9708, a novel, Investigational Oral Proteasome Inhibitor, in patients with relapsed or refractory light-chain amyloidosis (AL): results of a phase 1 study. ASH Annual Meeting Abstracts 2012; 120: 731.","journal-title":"ASH Annual Meeting Abstracts"},{"key":"BFbcj201471_CR17","doi-asserted-by":"publisher","first-page":"S147","DOI":"10.1016\/S0959-8049(11)70822-X","volume":"47","author":"PC Smith","year":"2011","unstructured":"Smith PC, Infante JR, Siu LL, Sullivan D, Vlahovic G, Kauh J et al. 1210 POSTER phase 1 study of MLN9708, an Investigational Proteasome Inhibitor, in advanced nonhematologic malignancies- updated results. Eur J Cancer 2011; 47: S147 (abstract ).","journal-title":"Eur J Cancer"},{"key":"BFbcj201471_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579\u2013586.","journal-title":"J Clin Oncol"},{"key":"BFbcj201471_CR19","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/46.5.673","volume":"46","author":"ES Lightcap","year":"2000","unstructured":"Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ . Proteasome inhibition measurements: clinical application. Clin Chem 2000; 46: 673\u2013683.","journal-title":"Clin Chem"},{"key":"BFbcj201471_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1182\/blood-2009-08-233155","volume":"115","author":"N Di Bella","year":"2010","unstructured":"Di Bella N, Taetle R, Kolibaba K, Boyd T, Raju R, Barrera D et al. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood 2010; 115: 475\u2013480.","journal-title":"Blood"},{"key":"BFbcj201471_CR21","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867\u20134874.","journal-title":"J Clin Oncol"},{"key":"BFbcj201471_CR22","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1365-2141.2009.07775.x","volume":"146","author":"J Gerecitano","year":"2009","unstructured":"Gerecitano J, Portlock C, Moskowitz C, Hamlin P, Straus D, Zelenetz AD et al. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol 2009; 146: 652\u2013655.","journal-title":"Br J Haematol"},{"key":"BFbcj201471_CR23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","volume":"23","author":"A Goy","year":"2005","unstructured":"Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667\u2013675.","journal-title":"J Clin Oncol"},{"key":"BFbcj201471_CR24","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","volume":"23","author":"OA O'Connor","year":"2005","unstructured":"O'Connor OA, Wright J, Moskowitz C, Muzzy J, Gregor-Cortelli B, Stubblefield M et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676\u2013684.","journal-title":"J Clin Oncol"},{"key":"BFbcj201471_CR25","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","volume":"24","author":"SJ Strauss","year":"2006","unstructured":"Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006; 24: 2105\u20132112.","journal-title":"J Clin Oncol"},{"key":"BFbcj201471_CR26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011; 12: 431\u2013440.","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"BFbcj201471_CR27","first-page":"Abstract P-197","volume":"96","author":"N Gupta","year":"2011","unstructured":"Gupta N, Riordan W, Berger A, Liu G, Berg D, Kalebic T et al. Clinical pharmacokinetics (PK)\/pharmacodynamics (PD) of intravenous (IV) and oral (PO) MLN9708, an investigational proteasome inhibitor, in four phase 1 monotherapy studies. Haematologica 2011; 96((suppl 1)): Abstract P-197.","journal-title":"Haematologica"},{"key":"BFbcj201471_CR28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1159\/000322866","volume":"79","author":"I Hrusovsky","year":"2010","unstructured":"Hrusovsky I, Emmerich B, von Rhee A, Voegeli J, Taverna C, Olie RA et al. Bortezomib retreatment in relapsed multiple myeloma\u2014results from a retrospective multicentre survey in Germany and Switzerland. Oncology 2010; 79: 247\u2013254.","journal-title":"Oncology"},{"key":"BFbcj201471_CR29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/bjh.12198","volume":"160","author":"MT Petrucci","year":"2013","unstructured":"Petrucci MT, Giraldo P, Corradini P, Teixeira A, Dimopoulos MA, Blau IW et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol 2013; 160: 649\u2013659.","journal-title":"Br J Haematol"},{"key":"BFbcj201471_CR30","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/ajh.21517","volume":"84","author":"R Sood","year":"2009","unstructured":"Sood R, Carloss H, Kerr R, Lopez J, Lee M, Druck M et al. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. Am J Hematol 2009; 84: 657\u2013660.","journal-title":"Am J Hematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201471.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201471","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201471.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T22:52:43Z","timestamp":1672959163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,17]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10]]}},"alternative-id":["BFbcj201471"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2014.71","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,17]]},"assertion":[{"value":"1 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SE Assouline has received research funding from Roche and Novartis. BD Cheson has served as an advisory board member for Millennium: The Takeda Oncology Company. S Hamburg and R Reyes declare no potential conflicts of interest. J Chang has received research funding from Genentech and Celgene. R Rifkin has served as an advisory board member for Millennium: The Takeda Oncology Company, Onyx, and Celgene, and has received payment for lectures including service on speakers' bureaus for Millennium: The Takeda Oncology Company, Celgene, INCYTE, and Amgen. P Martin has received payment for lectures including service on speakers' bureaus for Millennium: The Takeda Oncology Company.A-M Hui, J Yu, N Gupta, A Di Bacco, and Y Shou are employed by Takeda Pharmaceuticals International Co., Cambridge, MA.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}